newsfilter
← Latest News
PR Newswire·

Orexo develops a nasal adrenaline medication based on the novel amorphOXTM platform

UPPSALA, Sweden, Dec. 2, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX:ORXOY) today announces it has initiated a new pharmaceutical development project, OX640, a nasal adrenaline product for the emergency treatment of allergic reactions. Ad